OSI Pharmaceuticals (OSIP) - formerly Oncogene Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LLCF who wrote (78)	1/5/2000 9:10:00 AM
From: scaram(o)uche	Read Replies (1) of 447

>> I'm still focused on the patent claims << see the old discussion in the (?) BVF thread, and........ Message 12403551 :-) biz.yahoo.com Wednesday January 5, 7:30 am Eastern Time Company Press Release SOURCE: OSI Pharmaceuticals, Inc. OSI Pharmaceuticals Licenses Gene Transcription Patent Estate to the R.W. Johnson Pharmaceutical Research Institute UNIONDALE, N.Y., Jan. 5 /PRNewswire/ -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP - news) announced today that it has signed a non-exclusive licensing agreement with the R.W. Johnson Pharmaceutical Research Institute, a Johnson & Johnson (NYSE: JNJ - news) company, covering OSI's gene transcription patent estate. Under the terms of the agreement, OSI will receive annual fees together with milestones and success payments from small molecule gene transcription modulators developed and marketed as pharmaceutical products. Modulation of gene transcription is a process in which compounds increase or decrease the activity of a target gene and subsequent protein production, which can result in a therapeutic effect. (snip)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next